FDA Advisory Committees Decline & Biosimilar Rule Changes
FDA faces scrutiny over a 63% drop in advisory committee meetings in 2025 and new moves to ease biosimilar development requirements in 2026.
Clinical Research
The latest clinical research coverage from Hawaii Medical Journal.
Antihypertensive Deprescribing in Nursing Home Residents: Evidence for Individualized Blood Pressure Management in Frail Elderly Populations
A randomized controlled trial demonstrates that systematic reduction of antihypertensive medications in nursing home residents may be safely implemented without adverse cardiovascular outcomes. These findings challenge current guidelines and support individualized blood pressure targets in frail elderly populations.
Long-Acting Injectable Antiretroviral Therapy Demonstrates Efficacy in HIV Patients with Adherence Challenges: A Critical Analysis
A randomized controlled trial of cabotegravir plus rilpivirine demonstrates non-inferior virologic suppression compared to daily oral therapy in HIV patients with documented adherence difficulties. The findings support expanded use of long-acting injectable regimens in select populations.
Leadership Transition in Global Sexual and Reproductive Health: Clinical Implications of the New IPPF Directorate for Underserved Populations
The appointment of Maria Antonieta Alcalde Castro as Director General of the International Planned Parenthood Federation represents a strategic leadership transition with potential implications for global sexual and reproductive health service delivery to underserved populations.
Global Health Financing Shortfalls: Implications for Infectious Disease Control in Pacific Island Communities
The Global Fund's recent replenishment shortfall of $5.36 billion below target demonstrates systemic challenges in international health financing that may disproportionately affect resource-limited Pacific Island populations.
In Vivo Base Editing for Familial Hypercholesterolemia: Early Evidence from a Phase 1 Trial
A phase 1 trial of YOLT-101 gene therapy demonstrated sustained reductions in PCSK9 and LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia, though larger studies are required to establish clinical efficacy.
Bimagrumab Plus Semaglutide for Obesity Management: Analysis of a Phase 2 Randomized Controlled Trial Demonstrating Enhanced Weight Reduction with Lean Mass Preservation
A phase 2 randomized controlled trial demonstrated that the combination of bimagrumab and semaglutide achieved superior weight reduction compared with semaglutide monotherapy while preserving lean muscle mass. The combination therapy resulted in a least squares mean weight loss of 17.8 kg versus 14.2 kg with semaglutide alone at 48 weeks.